VivoSeq
Oncology

GIST - Gastrointestinal Stromal Tumor

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

GIST - Gastrointestinal Stromal Tumor is an early-stage landscape with 2 programs across 2 companies. The most active players are Kumquat Biosciences Inc., Novartis.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kumquat Biosciences Inc.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

KQB198

Kumquat Biosciences Inc.

Imatinib

Novartis

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Protein / enzyme150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
Recruiting·KKumquat Biosciences Inc.·Phase 2·NCT07406633·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)